ACOTEC-B (06669) has issued a profit warning, projecting a net loss of no more than 80.9 million yuan for the six months ending June 30, 2026. This marks a sharp reversal from the net profit of approximately 88.6 million yuan recorded in the same period in 2025.

The expected swing from profit to loss is primarily driven by the termination of the U.S. clinical trial program for the AcoArt Litos® Paclitaxel-Coated PTA Balloon Catheter. This decision has triggered a one-time non-cash impairment loss on capitalized R&D spending and a provision for related expenses, totaling roughly 151 million yuan.

Management concluded that changes in the future product pipeline and U.S. market dynamics could limit the product's profitability, making termination commercially prudent. The group is now focusing resources on its other pipeline candidates and is exploring new overseas opportunities with commercial partners, with further details to be provided in due course.